ClinicalTrials.gg
CompletedNCT00875394Updated May 30, 2017Results posted

Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

A Phase 3 interventional study of sitagliptin phosphate and Comparator: metformin in Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Feb 2007, registered Apr 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
30 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
117th of 197
68 · median 102
Started
2007
with 16 others
Phase 3
74 of 198
none open now
Registered
66th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 117th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 66th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 30 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

After 24 weeks of treatment, to assess the A1C-lowering efficacy of sitagliptin 100 mg once daily added to the regimen of patients with inadequate glycemic control on metformin monotherapy

03

Conditions studied

  • Diabetes Mellitus, Non-Insulin-Dependent
04

Who can participate

Ages eligible
30 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient Has Type 2 Diabetes Mellitus
  • Patient Is 30-78 Years Of Age On The Day Of Signing
  • Patient Is Currently On Metformin Therapy (1500 Mg/Day)
  • Patient Is A Male Or A Female Who Is Unlikely To Conceive, As Indicated By At Least One Yes Answer To The Following Questions: A) Patient Is A Male. B) Patient Is A Surgically Sterilized Female. C) Patient Is A Female 45 Years Of Age With >2 Years Since Last Menses. D) Patient Is A Non-Sterilized Premenopausal Female And Agrees To Use An Adequate Method Of To Prevent Pregnancy Throughout The Study Starting With Visit 1 And For 14 Days After The Last Dose Of Study Medication
  • Patient Understands The Study Procedures, The Alternative Treatments Available, The Risks Involved In The Study And Voluntarily Agrees To Participate By Giving Written Informed Consent
  • Patient Has An A1c of 6.5 % - 11.0%

Exclusion criteria

Exclusion Criteria:

  • Patient Has A History Of Type 1 Diabetes Mellitus Or History Of Ketoacidosis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    1

    sitagliptin + metformin

    Drug: sitagliptin phosphate · Drug: Comparator: metformin

  • Active comparator
    2

    metformin + any other oral antidiabetic drug

    Drug: Comparator: metformin · Drug: Comparator: Antidiabetic Standard of Care

  • Active comparator
    3

    metformin

    Drug: Comparator: metformin

Interventions

  • sitagliptin 100 mg Once a day (QD) for 24 weeks

    Also known as: sitagliptin

  • metformin 850 mg Twice a day (BID) for 24 weeks

    Also known as: metformin

  • metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks

    Also known as: metformin

  • DrugComparator: Antidiabetic Standard of Care

    Patient can take any oral antidiabetic drug (other than metformin)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24

    Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values.

    Time frame: Baseline and 24 weeks

07

Results

Posted Apr 20, 2011
Limitations and caveats
A limited number of participants were recruited into this open-label study. This study was conducted at a single site. Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.

Participant flow

Patients were recruited in Principal Investigator's private practice, in Mexico City. First Patient Entered: 15 Feb 2007. Last Patient's Last Visit: 27 Jun 2008

Participant flow — Overall Study
MilestoneSitagliptin + MetforminMetformin + Any Non-DPP-4i Oral Antidiabetic DrugMetformin Alone
Started36239
Completed36239
Not completed000

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24

Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values.

Time frame:
Baseline and 24 weeks

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin + Metformin—0/36 (0%)0/36 (0%)
Metformin + Any Non-DPP-4i Oral Antidiabetic Drug—0/23 (0%)1/23 (4.3%)
Metformin Alone—0/9 (0%)0/9 (0%)
Most frequent other events
Most frequent other events
EventSitagliptin + MetforminMetformin + Any Non-DPP-4i Oral Antidiabetic DrugMetformin Alone
NauseaGastrointestinal disorders0/361/230/9
CoughRespiratory, thoracic and mediastinal disorders0/361/230/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin + MetforminMetformin + Any Non-DPP-4i Oral Antidiabetic DrugMetformin AloneTotal
Mean54.2 ± 9.856.0 ± 8.553.3 ± 11.754.69 ± 9.55
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin + MetforminMetformin + Any Non-DPP-4i Oral Antidiabetic DrugMetformin AloneTotal
Female2519650
Male114318
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m2)Sitagliptin + MetforminMetformin + Any Non-DPP-4i Oral Antidiabetic DrugMetformin AloneTotal
Mean29.0 ± 4.528.8 ± 5.128.3 ± 5.228.84 ± 4.74
Glycosylated Hemoglobin A1C (A1C)
Glycosylated Hemoglobin A1C (A1C)(Percent)Sitagliptin + MetforminMetformin + Any Non-DPP-4i Oral Antidiabetic DrugMetformin AloneTotal
Mean8.8 ± 1.58.0 ± 1.88.2 ± 1.18.47 ± 1.61
Time since diagnosis of diabetes
Time since diagnosis of diabetes(Years)Sitagliptin + MetforminMetformin + Any Non-DPP-4i Oral Antidiabetic DrugMetformin AloneTotal
Mean8.9 ± 7.16.8 ± 8.510.9 ± 7.78.43 ± 7.68
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2007 to primary completion in Jun 2008, 16 months.

Results were first posted in Apr 2011, 2 years 9 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2009
First posted
Apr 3, 2009
StartActual
Feb 1, 2007
Primary completionActual
Jun 27, 2008
CompletionActual
Jun 27, 2008
Results first posted
Apr 20, 2011
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00875394
Responsible party
Sponsor
First posted
Apr 3, 2009
Start date
Feb 1, 2007
Primary completion
Jun 27, 2008
Completion
Jun 27, 2008
Results posted
Apr 20, 2011
Last update
May 30, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion